The CFO's $3.48M sale is the largest insider transaction at RPRX in the past 30 days, but at 0.01% of market cap it is not material. The timing just after a credit facility refinancing suggests the sale may be liquidity-driven (e.g., tax planning, diversification) rather than informed selling. Monitor for any additional insider sales in the coming weeks, particularly if the CFO sells again at higher volumes. The 88% analyst bullish consensus and strong historical win rate (67% T+20) on this ticker suggest the cluster is not a sell signal.
Price Chart
Executive Summary
Two senior executives at Royalty Pharma sold a combined $4.2M in open-market sales over a 7-day window, including the CFO selling $3.48M. The sales occurred just after the company closed a $1.8B credit facility refinancing, which insiders would have been aware of. While the dollar amount is modest relative to the $31.1B market cap (0.01%), the CFO's sale is notable for its size and timing, though it may reflect routine portfolio rebalancing post-refinancing rather than a bearish signal.
Key Financial Metrics
Key Facts
- CFO Terrance Coyne sold 64,399 shares at $53.98 for $3.48M on 2026-05-26
- EVP Marshall Urist sold 13,700 shares at $52.75 for $722K on 2026-05-20
- Total insider sales of $4.2M represent ~0.01% of RPRX's $31.1B market cap
- Sales occurred 4 days after Royalty Pharma closed a $1.8B credit facility refinancing (8-K filed 2026-05-28)
- No open-market purchases were reported in the cluster window
Financial Impact
Total insider sales of $4.2M, or 0.01% of market cap — immaterial relative to company size
Risk Factors
- CFO selling $3.48M in a single transaction could indicate personal portfolio rebalancing, but if followed by additional C-suite sales, it may signal reduced conviction
- Insider sales are generally weak predictors of future returns per academic literature, especially when clustered near corporate events like refinancings
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-RPRX-1780001336204 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 4, 2026 27d ago | Press Release | $60.59 $58.47 | ▲ +3.50% | ▲ +2.38% | $57.16 (+5.66%) |
Aug 19, 2026 6w ago | Insider Cluster | $61.73 $61.80 | ▲ +0.11% | ▲ +0.50% | $57.16 (−7.40%) |
Aug 12, 2026 7w ago | 144 | $58.56 $60.58 | ▲ +3.45% | ▲ +5.41% | $57.16 (−2.39%) |
Aug 5, 2026 8w ago | 8-K | $57.75 $59.22 | ▲ +2.55% | ▲ +2.19% | $57.16 (−1.02%) |
Jul 2, 2026 13w ago | Insider Cluster | $57.77 $57.96 | ▲ +0.33% | ▼ −0.60% | $57.16 (−1.06%) |
Jul 2, 2026 13w ago | Insider Cluster | $57.77 $57.96 | ▲ +0.33% | ▼ −0.60% | $57.16 (−1.06%) |
May 28, 2026 18w ago | Insider Cluster | $55.76 $55.87 | ▲ +0.20% | ▲ +2.72% | $57.16 (+2.51%) |
May 28, 2026 18w ago | 8-K | $55.76 $54.97 | ▼ −1.42% | ▼ −1.12% | $57.16 (+2.51%) |
May 22, 2026 19w ago | Insider Cluster | $54.50 $55.18 | ▲ +1.25% | ▼ −0.41% | $57.16 (+4.88%) |
May 15, 2026 20w ago | Insider Cluster | $52.07 $53.86 | ▲ +3.44% | ▲ +1.82% | $57.16 (+9.78%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access